Pharmacokinetics of depot medroxyprogesterone acetate contraception

被引:0
|
作者
Mishell, DR [1 ]
机构
[1] UNIV SO CALIF,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90089
关键词
depo-medroxyprogesterone acetate; DMPA; contraception; injectable contraception; pharmacokinetics; pharmacodynamics; estradiol; ovulation; fertility; endometrium;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Depot medroxyprogesterone acetate (DMPA) is ail aqueous suspension of 17-acetoxy 6-methyl progestin administered by intramuscular injection for long-term contraception. This highly effective injectable formulation of medroxyprogesterone acetate (MPA) has a prolonged duration of action since the progestin is released slowly from the muscle. MPA is detected in the serum within 30 minutes after an injection of 150 mg. Serum concentrations vary between individual women but generally plateau at about 1.0 ng/mL for about three months, after which there is a gradual decline. In some women, MPA can be detected in the serum for as long as nine months after a single injection of 150 mg. The circulating MPA initially inhibits the midcycle leutinizing hormone (LH) peak, but LH and follicle stimulating hormone (FSH) levels remain in the range of those for the luteal phase of a pretreatment control cycle. Since ovulation is inhibited, serum progesterone levels remain low (< 0.4 ng/mL) for several months following an injection of DMPA. When MPA levels fall below 0.1 ng/mL, ovulation resumes. Thus, return to fertility is delayed for several months if a woman wishes to conceive after receiving one or move injections of DMPA. Following an injection of DMPA, serum estradiol levels initially are in the early to midfollicular phase range (mean approximately 50 pg/nL). Serum estradiol levels begin to rise about four months after a single injection when MPA levels fall below 0.5 ng/mL. For women who have used DMPA for several years, serum estradiol levels range between 10 and 92 pg/mL, with mean levels of about 40 pg/mL. Despite these low levels of estradiol, hot flushes are a rare event, and the vaginal epithelium remains moist and well rugated. Women using DMPA for several years do not observe a change in breast size. DMPA causes the endometrium to become atrophic, with small, straight endometrial glands and decidualized stroma. The cervical mucus remains thick and viscid. DMPA is a very effective form of contraception because of its multiple mechanisms of action and slow release into the circulation.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [21] Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability
    Prabhakaran, Sujatha
    Sweet, Ashley
    CONTRACEPTION, 2012, 85 (05) : 453 - 457
  • [22] A prospective evaluation of the effects on bone of discontinuing depot medroxyprogesterone acetate contraception.
    Scholes, D
    LaCroix, AZ
    Ichikawa, LE
    Ott, SM
    Barlow, WE
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S384 - S384
  • [23] SAFETY OF DEPOT MEDROXYPROGESTERONE ACETATE
    BONHOMME, MG
    POTTS, DM
    FORTNEY, JA
    ALLEN, MY
    LANCET, 1991, 338 (8772): : 942 - 942
  • [24] Depot medroxyprogesterone acetate galactorrhea
    Cromwell, P
    Anyan, W
    JOURNAL OF ADOLESCENT HEALTH, 1998, 23 (02) : 61 - 61
  • [25] TOXICOLOGY OF DEPOT MEDROXYPROGESTERONE ACETATE
    JORDAN, A
    CONTRACEPTION, 1994, 49 (03) : 189 - 201
  • [26] Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users
    Thurman, Andrea R.
    Schwartz, Jill L.
    Brache, Vivian
    Chen, Beatrice A.
    Chandra, Neelima
    Kashuba, Angela D. M.
    Weiner, Debra H.
    Mauck, Christine
    Doncel, Gustavo F.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 80 (01) : 79 - 88
  • [27] SUPPRESSION OF SPERM FUNCTION BY DEPOT MEDROXYPROGESTERONE ACETATE AND TESTOSTERONE ENANTHATE IN STEROID MALE CONTRACEPTION
    WU, FCW
    AITKEN, RJ
    FERTILITY AND STERILITY, 1989, 51 (04) : 691 - 698
  • [28] The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health
    Guilbert, Edith R.
    Brown, Jacques P.
    Kaunitz, Andrew M.
    Wagner, Marie-Soleil
    Berube, Jocelyn
    Charbonneau, Louise
    Francoeur, Diane
    Gilbert, Andree
    Gilbert, Francois
    Roy, Genevieve
    Senikas, Vyta
    Jacob, Robert
    Morin, Real
    CONTRACEPTION, 2009, 79 (03) : 167 - 177
  • [29] Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection
    Morroni, C
    Grams, M
    Tiezzi, L
    Westhoff, C
    CONTRACEPTION, 2004, 70 (01) : 19 - 23
  • [30] PHARMACIST ATTITUDES TOWARDS ADMINISTRATION OF DEPOT-MEDROXYPROGESTERONE ACETATE FOR CONTRACEPTION IN THE OUTPATIENT SETTING
    Ellenberg, K.
    Vij, R.
    CONTRACEPTION, 2024, 139